NEW YORK (GenomeWeb News) – Cepheid today said that the US Food and Drug Administration has categorized the firm's Xpert CT/NG test as moderate complexity under the Clinical Laboratory Improvement Amendments.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.